Varenicline (Champix®) Special Investigation (Regulatory Post Marketing Commitment Plan)

Pfizer

Status: Completed

Conditions: Smoking Cessation

Treatments: Drug: varenicline

Study type: Observational

Funder types: Industry

Identifiers

NCT01061710

A3051117

Details and patient eligibility

About

The purpose of this study is to collect the efficacy and safety information in subjects who have been retreated with varenicline (Champix®) within 52 weeks of initial treatment for their appropriate use in daily practice and are participants for varenicline Drug Use Investigation protocol A3051109 ((NCT# NCT00772941).

Full description

The subjects have been retreated with varenicline within 52 weeks, and subjects have been enrolled to varenicline Drug Use Investigation protocol A3051109.

Enrollment: 20 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or Female subjects intend to quit tobacco use who are prescribed varenicline (Champix®) by their Physicians
• Subjects who are prescribed varenicline (Champix®) for the second time within 52 weeks of initial treatment.

Exclusion criteria

Non-participants of varenicline (Champix®) Drug use Investigation protocol A3051109.

Trial design

20 participants in 1 patient group

varenicline (Champix®)

Description:

Subjects who have been retreated with varenicline within 52 weeks and have been enrolled to varenicline protocol A3051109.

Treatment:

Drug: varenicline